NextBillion - An Initiative of the William Davidson Institute at the University of Michigan

Friday, January 15, 2016

Sanofi Pasteur is supporting the Project by providing research funding to oversee, coordinate and conduct the scientific and administrative activities of the Human Vaccines Project Research Program this year. The funds will be used by the Project to launch and execute pilot studies, build partnerships with and across the stakeholder community, and set up the infrastructure and operational support for the Human Vaccines Project Research Program, according to Sanofi.

The Project, which has been endorsed as potentially transformative by 35 of the world’s leading vaccine scientists, seeks to raise $1 billion over a decade. The Project was incubated at the International AIDS Vaccine Initiative (IAVI) and is supported by leading academic research centers, industrial partners, and nonprofits to address the primary scientific barriers to developing new vaccines and immunotherapies.

“Sanofi Pasteur is proud to join this effort to accelerate and transform vaccine development for major and emerging infectious diseases as well as to better understand human immunology, which may be applicable toward disease management of other chronic disease states,” commented Jim Tartaglia, PhD, Sanofi Pasteur’s R&D Vice President for New Vaccine Projects. “The Project’s partnerships with industrial and non-profit product developers are key to ensuring that technological breakthroughs are rapidly translated into new products.”

As a member of the Industry Advisory Committee, Sanofi Pasteur will provide input on the Human Vaccines Project Research Program, review both published and unpublished data, and participate at various scientific workshops to be held by the Project. Sanofi Pasteur will be represented by R&D Vice President for Translational Science & Biomarkers Kent Kester, M.D.